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MITCHELL, I.J. AND C.B. CARROLL. Reversal of parkinsonian symptoms in primates by antagonism of excitatory amino acid 
transmission: potential mechanisms of action. NEUROSCI BIOBEHAV REV 21(4) 469-475,1997-Pxkinsonism is charactetised by 
overactive glutamatergic transmission in the cortico-striatal and subtbalamo-medial pallidal pathways. Local blockade of glutamatergic 
transmission in these pathways can alleviate parkinsonian symptoms. The effectiveness of the treatment, however, is often limited by the 
simultaneous appearrmce of unwanted side-effects. These side-effects, including ataxia and dissociative anaesthesia, are particularly 
problematic when N-methyl-o-aspartate (NMDA) antagonists are used. In an attempt o overcome these problems we have attempted to 
manipulate excitatory iamino acid (EAA)-mediated neurotransmission indirectly by targeting the NMDA receptor associated modulatory 
sites. We review evidence which demonstrates that antagonists for both the NMDA associated glycine and polyamine sites can reverse 
parkinsonian symptoms when injected intra-cerebrally in both MPTP-treated and bilateral 6-OHDA lesioned marmosets without 
eliciting unwanted side-effects. We further review preliminary data which suggest that ifenprodil, a polyamine site antagonist, has 
striking anti-parkinsonian actions in the marmoset. Potential mechanisms of action underlying these effects are discussed in terms of 
NMDA receptor subtypes and the neuroanatomical ocus of action. The anti-parkinsonian efficacy of intra-striatally administered EAA 
antagonists leads us to question the view of dopamine acting in the striatum as a simple neuromodulator. 0 1997 Elsevier Science Ltd. 
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1. THE ROLE OF EAAS IN THE PATHOPHYSIOLOGY OF PARKINSONISM 
THE last 10 years have seen great advances in our under- 
standing of the pathophysiology of parkinsonism. Studies 
using unit recording (35,59), in situ hybridization (2) and 2- 
deoxyglucose metabolic mapping (36,47) approaches in 
primate models of parkmsonism have enabled much of the 
neural circuitry which mediates the motor manifestations of 
parkinsonism to be mapped (for review see (1)). 
This work has pointed to the importance of excess exci- 
tatory amino acid (EAA)-mediated transmission i mediat- 
ing parkinsonian symptoms within two critical neuronal 
populations within the lbasal ganglia. The parkinsonian 
brain is firstly characterised by abnormally high levels of 
EAA-mediated activity in the projection from the subthala- 
mic nucleus to the mediall segment of the globus pallidus. 
Secondly, striatal neurona re abnormally overactive due to 
an excess of EAA-mediated corticostriatal transmission. 
This excess striatal activity is, however, restricted to only 
one of the subpopulations of striatal output neurons, that is 
the enkephalin positive striatal neurons which project o the 
lateral segment of the globus pallidus (2,17,18,24,49). The 
remainder of the striatal projection neurons are, in contrast, 
assumed to be abnormally underactive in experimental 
parkinsonism. These neurons are thought o be the dynor- 
phin-expressing neurons which project directly to the 
medial segment of the globus pallidus (l&24). 
2. EAA ANTAGONISTS CAN MODM PARKINSONIAN SYMPTOMS 
From the physiological studies outlined above it could be 
hypothesised that reduction of EAA-mediated transmission 
would alleviate parkinsonian symptoms. Support for such a 
hypothesis can be found in the literature where EAA antago- 
nists have been administered to parkinsonian rodents and 
primates by both systemic and intracerebral routes. 
MK-801 (( -I- )-5-methyl-lo, l l-dihydro-5H-diben- 
zo[a,&yclohept-5,10-imine maleate) (a non-competitive 
NMDA (N-methyl-n-aspartate) r ceptor antagonist), has 
been shown to increase locomotion in monoamine-depleted 
rodents following systemic injection (8,9) Similarly, sys- 
temically administered NBQX (2,3-dihydroxy-6-nit-7- 
sulfamoyl-benzo-(F) quinoxaline) (an EAA antagonist 
with selectivity for the AMPA (cY-amino-3-hydroxy-5- 
methyl-4-isoxazole propionate) receptor), has been reported 
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to decrease parkinsonian symptoms in the MPTP (1-methyl- 
4-phenyl-l,2,3,6-tetrahydropyridine)-treated macaque (26). 
Others, however, have failed to replicate this effect. For 
example, Luquin et al. reported a lack of anti-parkinsonian 
effect of NBQX when systemically administered toMPTP- 
treated macaques, the drug instead inducing lethargy and 
myoclonic jerks (31). 
Much of our own work has concentrated oninvestigating 
the effects of intracerebrally administered EAA antagonists. 
In these studies we have demonstrated that antagonism of 
EAA transmission within the medial pallidal segment of the 
MPTP-treated marmoset using either kynurenic acid (broad 
spectrum EAA antagonist) or 7-chlorokynurenate (an 
antagonist at the NMDA-associated glycine site) can result 
in a dramatic, but temporary, amelioration of parkinsonian 
symptoms (6,38). Kynurenate was also effective in rever- 
sing the motor symptoms of parkinsonism when injected 
into the medial pallidal segment of the MPTP-treated 
macaque (19). In related rodent studies we have demon- 
strated that unilateral intrastriatal injections of both D-CPP 
(a competitive NMDA receptor antagonist), and (R)-HA- 
966 (1-hydroxy-3-aminopyrrolid-2-one) (a glycine-site par- 
tial agonist) can induce locomotion in reserpine-treated an  
rotation in unilaterally 6-OHDA (6-hydroxydopamine)- 
lesioned rats (10). 
3. PoTErcnAL LIMITATIONS OF THE USE OF EAA ANTAGONIST IN THE 
TREATMENT OF PARKINSONISM 
From the studies mentioned above it is clearly feasible to 
alleviate parkinsonian symptoms in rodents and primates by 
either the systemic or intracerebral dministration of EAA 
antagonists, especially those acting at the NMDA receptor. 
However, the NMDA receptor has a widespread distribution 
throughout the central nervous ystem (33,63), reflecting its 
diverse functions. It might be expected, therefore, that such 
approaches to the symptomatic relief of parkinsonism will 
not be without problems, as targeting of specific populations 
of overactive neurons within the striatum and medial palli- 
dal segment following systemic administration of agents 
will be extremely difficult. 
Processes with which the NMDA receptor is known to be 
involved include long term potentiation within the hippo- 
campus, possibly associated with memory formation 
(12,13 ), neuronal pathway development (22), neurotoxicity 
(53) and induction of anaesthesia (34). In keeping with these 
reservations are observations ofdeficits that result from the 
pharmacological blockade of NMDA receptors in 
behavioural studies. 
Blockade of NMDA receptors is known to produce 
deficits in learning and memory (45,48). It has additionally 
been demonstrated that whilst the systemic administration 
of MK-801 to monoamine-depleted mice undoubtedly 
increases locomotion it does so at the cost of inducing 
ataxia (8). This occurs despite the suggestion that MK-801 
might be able to elicit a more specific behavioural effect by 
binding selectively to overactive NMDA receptors whose 
channels are open for longer (58). 
Further eports uggest that there are species differences 
in response to systemic NMDA antagonists, uch that MK- 
801 fails to exert an anti-parkinsonian ction in primates. 
Thus Crossman et al. (14), reported a failure of MK-801 to 
improve motor control in MPTP-treated macaques, the drug 
instead producing a sedative-like effect. Similarly, Domino 
and Sheng (15) reported a slight effect on rotation behaviour 
when MK-801 was administered to MPTP-induced hemi- 
parkinsonian macaques, though the animals became cata- 
leptic at higher doses. Equally disappointing results have 
come from MPTP-treated marmoset studies where MK-801 
has failed to reverse parkinsonism but induced ataxia (11). 
Similarly, competitive NMDA receptor antagonists, uch as 
CGP 40.116, given alone to MPTP-treated marmosets failed 
to improve motor performance but elicited ataxia (61). 
Systemic injection of MK-801 in cynomologous monkeys 
and squirrel monkeys has also been shown to result in 
sedation and ataxia (54). 
Local antagonism of EAA-mediated transmission i par- 
kinsonian rats by injections of either kynurenic acid into the 
medial pallidal segment (6) or CPP into the striatum (10) 
also induced side-effects which compromised the anti- 
parkinsonian effects of the manipulations. In these instances 
the alleviation of parkinsonian symptoms proceeds in a dose 
related manner until the drug starts to induce sedative 
effects. 
4. ALTERNATIVE APPROACHES TO THE MANIPULATION OF 
NMDA-MEDIATED TRANSMISSION 
The above considerations have caused us to explore ways 
in which NMDA receptor-mediated transmission can be 
modified in a more selective manner. It is now recognised 
that there are subtypes of NMDA receptor, each with its 
own neuroanatomical distribution. This heterogeneity of
NMDA receptors can potentially be utilised to target hose 
receptor populations which are abnormally overactive in 
parkinsonism. In addition, it is known that the different 
subtypes of NMDA receptor are differentially modulated 
by agents acting at the various NMDA receptor-associated 
binding sites, and this may provide further targets for selec- 
tive pharmacological intervention. 
4.1. Subtypes of NMDA receptors 
There are two main families of subunits for the NMDA 
receptor. In the rat these are known as NMDA-R1 (44) and 
NMDA-R2 (28). There are currently known to be at least 
eight splice variants of the NMDA-R1 subunit (44,57,62) 
which is thought o contain the agonist binding sites for 
glutamate and glycine, and is therefore necessary for for- 
mation of a functional receptor (62). There are four known 
NMDA-R2 subunits, A-D, which confer functional 
diversity on the NMDA receptor complex (43,23). It is 
thought hat most of the functional NMDA receptors in the 
brain are heteromers, made up of NMDA-R1 and NMDA- 
R2 subunits. 
Both the different splice variants of the NMDA-R1 sub- 
unit and the different subtypes of NMDA-R2 subunits are 
reported to display differential regional distribution 
(23,43,46,56). Indeed the various cell types within the 
striatum are reported to express different NMDA receptor 
subunits (30). The different NMDA receptor subunits confer 
on the receptor different sensitivities to various antagonists, 
such that NMDA-R2C receptors are most sensitive to 7- 
chlorokynurenate and NMDA-R2A receptors are most 
sensitive to antagonism by AP-5 and Mg z+ (28). The 
NMDA-R2A and NMDA-R2B receptor subtypes are sug- 
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gested to display differing degrees of modulation by glycine 
(39,41). 
The differential regional distribution of NMDA receptors 
with different subunit composition may account for the inef- 
fectiveness of intrastriatally injected D-AP-5 in alleviating 
parkinsonian symptoms in rodents compared with D-CPP 
and (R)-HA-966 (10). D-AP-5 is known to have low affinity 
for the 'agonist-preferring' NMDA receptor subtype which 
contains the NMDA-R2B subunit (7,28,41) which is pre- 
valent in the striatum (39,56). 
The polyamine site associated with the NMDA receptor is
another potential target for therapeutic ntervention. The 
polyamine-site antagonist, ifenprodil, is thought to be selec- 
tive for NMDA receptors expressing the NMDA-R2B sub- 
unit (60). Thus ifenprodil might be able to exert selective 
effects on striatal NMDA receptors. Ifenprodil, in contrast 
to D-CPP, does not affect learning and memory formation in 
mice (48), suggesting that it might exhibit selectivity for an 
NMDA receptor subtype when administered systemically. 
These differences inthe composition of NMDA receptors 
in specific anatomical locations can thus be potentially 
exploited in order to achieve selective modulation of 
NMDA receptor-mediatedL transmission. 
4.2. NMDA receptor modMatory sites 
It is now well established that transmission atthe NMDA 
receptor-associated ion channel can be modified by the 
activity at modulatory sites. The diversity and complexity 
of these modulatory sites of the NMDA receptor may under- 
lie the different functions with which the NMDA receptor is 
known to be involved. The NMDA receptor complex can be 
considered to be made up of four domains: the glutamate 
binding site, the glycine binding site, the polyamine site and 
the ion channel. Associated with the channel are four nega- 
tive modulatory binding sites: the magnesium site, the zinc 
site, the site for protons, and the phencyclidine site for 
allosteric modulators. These sites not only affect ligand 
binding to the glutamate site and channel activation, but 
also interact with each other, resulting in complex modula- 
tory mechanisms (20,21,51,52,55). 
Glycine is a co-agonist for the NMDA receptor such that 
transmission can only take place at this receptor-ionophore 
complex if glycine is present (25). Recent work on differ- 
entiating subtypes of NMDA receptors has suggested that 
the interactions between the glutamate and glycine sites of 
the NMDA receptor are complex, such that different sub- 
types of NMDA receptors how different levels of modula- 
tion by glycine (39). Th:is raises the possibility of using 
glycine-site antagonists eselectively block transmission at
a subpopulation of NMDA receptor complexes. Manipula- 
tion of NMDA-mediated transmission by exploiting the 
glycine site is also an attractive possibility due to the 
availability of glycine-sil:e partial agonists. Such agents, 
which include (R)-HA-966 (50), could potentially be used to 
attenuate NMDA receptor-mediated transmission whilst 
allowing a basal evel to continue (16). 
4.3. Indirect modification of EAA-mediated transmission 
The release of EAAs in some brain areas is regulated 
presynaptically b the action of opiates. This characteristic 
can be potentially used in order to modify EAA trans- 
mission indirectly. Within the basal ganglia there are 
moderate-high densities of kappa opiate receptors. Electro- 
physiological studies in rat brain have shown that kappa 
opioid agonists reduce EAA release from presynaptic term- 
inals in globus pallidus and substantia nigra pars reticulata 
(32). Thus, kappa opiate agonists, such as the neuro- 
protective agent enadoline (CI-977) can potentially be 
used to block EAA release in the output structures of the 
basal ganglia and thus result in the symptomatic relief of 
parkinsonism. 
5. ANIMAL MODELS OF PARKINSONISM 
Investigations of whether these approaches tomodifying 
EAA-mediated transmission can alleviate parkinsonian 
symptoms need to be conducted in the first instance in an 
appropriate animal model. Several animal models of parkin- 
sonism are in routine use, all of which have advantages and 
limitations. There are concerns that parkinsonian primates 
may respond ifferently to rodents following the adminis- 
tration of NMDA receptor antagonists. For example, as 
cited above, systemically-administered MK-801 increased 
locomotion in monoamine-depleted mice but has no anti- 
parkinsonian effects in MPTP-treated macaques. Further- 
more, we have recently demonstrated that responses to 
drug treatment in reserpine-treated ro ents varies according 
to the reserpine administration protocol. We have thus 
shown that a double reserpine procedure, whereby asecond 
dose of reserpine is given after a one week recovery period, 
changes the anti-parkinsonian efficacy of both dopamine 
agonists and NMDA receptor antagonists such that the 
behavioural response seen is much greater after the second 
dose of reserpine than the first (10). As a consequence of
potential species differences of this type and reservations 
about the reserpine model we have conducted studies in 
parkinsonian primates where possible. 
We have used a novel bilateral 6-OHDA lesioned mar- 
moset model to investigate he possibility of relieving par- 
kinsonian symptoms by manipulation of EAA transmission 
by the use of glycine-site antagonists, polyamine-site 
antagonists and kappa opiate agonists. The model is pre- 
pared by making lesions of the medial forebrain bundle in 
a two-stage procedure where the interval between the 
lesions is two months. This procedure results in a stable, 
marked parkinsonian condition, which we have extensively 
characterised, without he occurrence of the major debilitat- 
ing features normally associated with bilateral 6-OHDA 
lesions (37). Marmosets treated in this manner have a 
hunched posture, show very little spontaneous movement, 
bradykinesia, freezing and difficulty in initiating move- 
ments but, with careful husbandry immediately following 
the second lesion, maintain their body weight o within 90% 
of preoperative alues. All of these parkinsonian symptoms 
can be alleviated, in a dose-dependent manner, by the 
systemic administration f levodopa. 
6. ANTI-PARKINSONIAN EFFECTS OF (R)-HA-966 
We have investigated the potential of the glycine-site 
partial agonist, (R)-HA-966, to alleviate parkinsonian symp- 
toms in the bilateral 6-OHDA lesioned marmoset (37). (R)- 
HA-966 was injected directly into the marmoset striatum, 
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into either the dorsolateral caudate nucleus or the ventrome- 
dial putamen. A dose-dependent reversal of parkinsonian 
symptoms was seen at both anatomical sites, the latency of 
onset being approximately 5 min. The maximal response was 
elicited by bilateral injections of 250 nmol (R)-HA-966. At 
this dose the animals' parkinsonian symptoms were comple- 
tely alleviated in the absence of stereotypy oranaesthetic-like 
side-effects, uch that motor behaviour was virtually normal. 
Indeed, intrastriatal injections of the partial glycine agonist 
were as effective as equivalent injections of the mixed D1/D2 
dopamine agonist, apomorphine. 
This effect of (R)-HA-966 is similar to that observed in 
rodent models of parkinsonism. We have demonstrated that 
equivalent intrastriatal injections of the drug elicit rotation 
behaviour in unilateral 6-OHDA lesioned rats and increase 
locomotion in reserpine-treated rats (10). We have further 
established that this effect can be blocked by the co-admin- 
istration of the glycine-site agonist, D-serine, which suggests 
that the anti-parkinsonian effects of (R)-HA-966 are indeed 
mediated via antagonism of the NMDA receptor-associated 
glycine site. 
(R)-HA-966 can also elicit an anti-parkinsonian ction in 
rodents when injected systemically. Our studies showed a 
slight alleviation of parkinsonian symptoms following sys- 
temic injection of the drug but these increases in mobility 
diminished with time due to a decrease in muscle tone 
which began to interfere with purposeful movement (10). 
Similarly, others have demonstrated that systemically 
injected (R)-HA-966 can ameliorate haloperidol-induced 
catalepsy (27). 
Disappointingly, we found no evidence to suggest hat 
(R)-HA-966 has an anti-parkinsonian ction when systemi- 
cally administered to bilateral 6-OHDA lesioned marmo- 
sets. Injections in the dose range 50-300 mg kg -1 (i.m.) 
had no effect on movement, with the exception of occa- 
sional stereotyped scratching movements, nor did they elicit 
any sedative or anaesthetic-like effects (37). It is not clear 
why (R)-HA-966 should be active when injected into the 
striatum and not when administered systemically, however 
it could reflect inability of this water-soluble compound to 
cross the blood-brain barrier in the primate. 
The absence of a sedative response seen after intrastriatal 
or systemic injection of (R)-HA-966 is in sharp contrast to the 
marked anaesthetic-like side-effects following both central 
and systemic injections of MK-801, D-CPP and kynurenic 
acid. One possible xplanation for the difference in response 
is that (R)-HA-966 is acting as a partial agonist in contrast to 
these other agents which act as NMDA receptor antagonists. 
(R)-HA-966 would thus be expected to allow a certain 
amount of NMDA-mediated transmission to take place 
which could presumably be sufficient o prevent he onset 
of sedation or anaesthesia. This explanation, attractive in its 
simplicity, however, -cannot account for some of our pre- 
liminary data on the action of 7-chlorokynurenate. This 
drug, a full glycine-site antagonist, alleviates parkinsonian 
symptoms when injected into the medial pallidal segment of 
the globus pallidus in the MPTP-treated marmoset in the 
absence of any side-effects (38). An alternative explanation 
of the efficacy of glycine-site antagonists in alleviating 
parkinsonian symptoms may lie in the ability of glycine to 
differentially modulate glutamate binding and activity at 
different subtypes of the NMDA receptor (39,40) reflecting 
different NMDA-R2 subunit composition. 
7. ANTI-PARKINSONIAN EFFECTS OF ANTAGONISM OF THE NMDA 
RECEPTOR-ASSOCIATED POLYAMINE SITE 
We have shown that systemic administration of the 
NMDA receptor-associated polyamine site antagonist, ifen- 
prodil, can exert a dramatic alleviation of parkinsonian 
symptoms in the bilateral 6-OHDA lesioned marmoset. A
dose of 12.5 mg kg -1 of ifenprodil (i.m.) resulted in short 
latency (10 min) and long duration (over 3 h) alleviation of 
parkinsonian symptoms. The animals' motor behaviour did 
not fully return to normal, which may indicate that this dose 
was not optimal. The drug, however, did not elicit any signs 
of sedation, anaesthesia, stereotypy or ataxia. It is also 
encouraging to note that ifenprodil, when systemically 
administered to rodents, does not impair working memory 
as measured by alteration behaviour in a Y-maze (48). 
Less encouraging with respect o the potential of polya- 
mine site antagonists oalleviate parkinsonian symptoms in 
human patients is a brief clinical paper which fails to report 
significant anti-parkinsonian effects following administra- 
tion of ifenprodil (42). The authors of this paper, however, 
emphasise both its preliminary nature and the potential 
problems of dose and/or pharmacokinetics of ifenprodil. 
8. ANTI-PARKINSONIAN EFFECTS OF KAPPA OPIOID AGONISTS 
We have investigated the potential of the kappa opiate 
agonist, enadoline (CI-977) in alleviating parkinsonian symp- 
toms in both rats and marmosets. We initially demonstrated 
that enadoline could increase mobility when injected into the 
medial pallidal segment of the MFrP-treated marmoset and 
the entopeduncular nucleus (the rodent homologue of the pri- 
mate medial pallidal segment) of the reserpine-treated rat (32). 
The presumed mechanism of action mediating these anti- 
parkinsonian responses i  binding of enadofine to presynaptic 
kappa opiate receptors on the terminals of the subthalamic 
nucleus neurons which project o the medial pallidal segment 
thereby blocking EAA release. 
More recently, we have shown that systemically injected 
enadoline can alleviate parkinsonian symptoms in the bilat- 
eral 6-OHDA lesioned marmoset (37). Injections of 
7.5 mg kg -1 (i.m.) resulted in a response with short latency 
(approximately 5 min) and duration of approximately 
40 min. This manipulation, however, failed to return the 
animals' behaviour completely to normal. The marmosets 
did show periods of normal behaviour but these were 
interrupted by bouts of slow repetitive jumping which 
were accompanied by a loss of co-ordination. These limited 
effects of enadoline in alleviating parkinsonism could be 
blocked by the co-administration f both naloxone, abroad 
spectrum opiate antagonist, and nor-binaltorphimine (nor- 
BNI), a specific kappa opiate antagonist. 
9. POTENTIAL MECHANISMS OF ACTION OF EAA ANTAGONISTS 1N 
REVERSING PARKINSONIAN SYMPTOMS 
From the brief review of the literature outlined above it 
is clear that blockade of EAA-mediated transmission 
using selective antagonists can alleviate parkinsonian 
symptoms in primates. Careful selection of the agent to 
be used may result in production of the desirable ffect in 
the absence of side-effects. The mechanism by which 
these agents exert their anti-parkinsonian effects can be 
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discussed at several evels including the neuroanatomical 
site of action and the effect on information processing 
within the basal ganglia as well as the pharmacological 
mode of action. 
It is clearly possible to alleviate parkinsonian symptoms 
in both the MPTP-treated~ marmoset and the bilateral 6- 
OHDA lesioned marmoset by making local injections of 
EAA antagonists into either the medial segment of the 
globus pallidus or the striatum. These findings are entirely 
in keeping with the model of the pathophysiology of 
parkinsonism that we artd others have advanced. This 
model argues that: (1) parkinsonian symptoms arise as a 
result of abnormally high rates of discharge in the striatal 
neurons which project o the lateral segment of the globus 
pallidus, and (2) these abnormal discharges result from 
excess of EAA-mediated transmission i  the afferents to 
these neurons. It is not possible, on the basis of the data 
reviewed here, to determine the neuroanatomical site of 
the anti-parkinsonian action of ifenprodil when injected 
systemically. The most likely candidates would, however, 
be the striatum and the medial pallidal segment. 
The effect of local maaipulation of EAA transmission 
within the medial segment: of the globus pallidus also par- 
allels the effects of surgical ablation of basal ganglia struc- 
tures in both idiopathic parkinsonian patients and 
experimental nimals. It has thus been demonstrated that 
selective destruction of the medial pallidal segment, which 
by definition must decrease the discharge rate of its neurons, 
alleviates parkinsonian syraptoms (29). Similarly, lesions of 
the subthalamic nucleus, which provide the EAA input to 
the medial pallidal segment, also result in symptomatic 
relief (4). These effects cala also be achieved in a reversible 
manner using high frequency stimulation which leads to a 
depolarisation blockade (3). 
Some researchers have argued that dopamine replace- 
ment therapy is capable of alleviating parkinsonian 
symptoms because dopamine acts in a neuromodulatory 
manner (5). Dopaminergic neurons in the nigrostriatal path- 
way are thus seen as forming a modulatory system within 
the brain which does not normally convey specific, tem- 
porally or spatially patterned messages. If dopamine does 
act in a neuromodulatory manner then dopamine replace- 
ment herapy for the treatment ofparkinsonism can function 
without he need to activate striatal dopamine receptors in a 
precise spatial and temporal manner. Rather, systematically 
administered dopamine agonists could just bathe the striatal 
dopamine receptors, which, provided the dose was in the 
correct range, would allow the complex ordered message 
from the cerebral cortex to once more cause the striatal 
projection eurons to discharge in an appropriate manner 
and thus alleviate parkinsonian symptoms. According to 
these intuitions it should not be possible to alleviate par- 
kinsonian symptoms by antagonising EAA transmission 
within the striatum as this would eradicate, or at least 
severely disrupt, the cortical message being sent to the 
striatum. The observation that local injection of (R)-HA- 
966 into the striatum reverses parkinsonian symptoms is 
hard to reconcile with this view of the functional organisa- 
tion of the striatum. Thus, the local application of the 
NMDA receptor-associated glycine-site partial agonist 
must exert its anti-parkinsonian effect by blocking the 
complex highly structured, spatially and temporally organ- 
ised cortical input. 
10. OVERVmW 
In summary, it is clear that EAA antagonists can be used 
to reverse parkinsonian symptoms in parkinsonian primates. 
The propensity of these antagonists o induce side-effects 
such as sedation and ataxia can be potentially overcome by 
using more selective antagonists such as the polyamine-site 
antagonist, ifenprodil. The ability of ifenprodil to alleviate 
parkinsonism in the bilateral 6-OHDA lesioned marmoset is
particularly promising and there is a pressing need to inves- 
tigate the potential anti-parkinsonian properties of related 
compounds. 
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